International

Tropical Storm Francine is active in the Gulf of Mexico and is expected to develop into a hurricane. These weather conditions may impact areas in the United States, including Alabama, Arkansas, Louisiana, Mississippi, Tennessee, and Texas. We continue to monitor and track the situation with our logistics partners to minimize challenges. Clients in the impacted areas should expect to be contacted directly if any routes are modified or canceled.

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Ewa Wysokinska, M.D., an assistant professor of medicine and consultant in the division of hematology and oncology at Mayo Clinic in Florida, to talk about clinical updates in thrombotic thrombocytopenic purpura.

This page lists updates posted to Mayo Clinic Labs during the month of August.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest advancements in Alzheimer’s disease testing and treatment.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They cover current trends, pain points, and opportunities for growth in the lab and diagnostics market.

William Morice II, M.D., Ph.D., recently joined the Advisory Board for a webinar discussion on 2024 lab market trends. Dr. Morice covered the current lab market outlook, the priority trends, and opportunities for future growth.

Register now – Nov. 12, 2024PACE / State of FL This webinar will cover metagenomic sequencing for diagnosing central nervous system infection. Content will be shared regarding technical details, clinical applications, and results interpretation, drawing on both current literature and practice guidelines.

In this month’s episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., interviews Jessica Stellmaker on creating a culture of continuous improvement using kaizen events. Discussion[...]

Mayo Clinic Laboratories has introduced a revolutionary diagnostic test for bile acid malabsorption, a significant contributor to chronic diarrhea. Developed by Dr. Michael Camilleri and Dr. Leslie Donato, this new bile acid malabsorption panel simplifies diagnosis and improves patient care by eliminating the need for special diets or prolonged stool collection. The test's effectiveness has been validated internationally, offering new treatment avenues for patients. Discover how this innovative test is transforming clinical practice and enhancing patient outcomes.

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

PACE/FLPresentation Recording Coming Soon In this “Future Direction of Laboratory Medicine” webinar, Maggie DiGuardo, M.D., and Justin Juskewitch, M.D., Ph.D., will review the current knowledge regarding sickle cell disease from its genetic cause to the myriads of effects it can have for affected individuals.